Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBT (2024 - 2025)

Kura Oncology (KURA) has disclosed EBT for 2 consecutive years, with -$80.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 370.54% to -$80.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$278.4 million, a 61.88% decrease, with the full-year FY2025 number at -$278.4 million, down 61.88% from a year prior.
  • EBT was -$80.9 million for Q4 2025 at Kura Oncology, down from -$74.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$17.2 million in Q4 2024 to a low of -$80.9 million in Q4 2025.